Valeric acid, 2-propyl-
Brand names,
Valeric acid, 2-propyl-
Analogs
Valeric acid, 2-propyl-
Brand Names Mixture
Valeric acid, 2-propyl-
Chemical_Formula
C8H16O2
Valeric acid, 2-propyl-
RX_link
http://www.rxlist.com/cgi/generic2/depakene.htm
Valeric acid, 2-propyl-
fda sheet
Valeric acid, 2-propyl-
msds (material safety sheet)
Valeric acid, 2-propyl-
Synthesis Reference
Oberreit, Ber.29, 1998 (1896)
Valeric acid, 2-propyl-
Molecular Weight
144.211 g/mol
Valeric acid, 2-propyl-
Melting Point
120 - 130 oC
Valeric acid, 2-propyl-
H2O Solubility
Slightly soluble (1.3 mg/mL)
Valeric acid, 2-propyl-
State
Solid
Valeric acid, 2-propyl-
LogP
2.549
Valeric acid, 2-propyl-
Dosage Forms
Capsule (250 mg); Syrup (250 mg drug/5mL syrup)
Valeric acid, 2-propyl-
Indication
For use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
Valeric acid, 2-propyl-
Pharmacology
Valproic Acid is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder. It is also used to treat migraine headaches and schizophrenia. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome. Valproic Acid is believed to affect the function of the neurotransmitter GABA (as a GABA transaminase inhibitor) in the human brain. Valproic Acid dissociates to the valproate ion in the gastrointestinal tract. Valproic acid has also been shown to be an inhibitor of an enzyme called histone deacetylase 1 (HDAC1). HDAC1 is needed for HIV to remain in infected cells. A study published in August 2005 revealed that patients treated with valproic acid in addition to highly active antiretroviral therapy (HAART) showed a 75% reduction in latent HIV infection.
Valeric acid, 2-propyl-
Absorption
Rapid absorption from gastrointestinal tract.
Valeric acid, 2-propyl-
side effects and Toxicity
Oral, mouse: LD50 = 1098 mg/kg; Oral, rat: LD50 = 670 mg/kg. Symptoms of overdose may include coma, extreme drowsiness, and heart problems.
Valeric acid, 2-propyl-
Patient Information
Since valproate products may produce CNS depression, especially when combined with another CNS depressant (eg, alcohol), patients should be advised not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.
Valeric acid, 2-propyl-
Organisms Affected
Humans and other mammals